29 Nov 2020
Viatris Response
5yThanks for your feedback. Now that Mylan and Upjohn have combined to form Viatris, we have a global portfolio of more than 1,400 molecules across a broad range of major therapeutic areas, including best-in-class, iconic brand-name products, as well as global key brands, generics, including branded and complex generics, biosimilars and over-the-counter offerings. We are uniquely positioned to help meet the world’s evolving healthcare needs, and it’s rewarding to be part of a team that is able to make a difference!